Credit Available: 1.00 AMA PRA Category 1 credit(s)

Course Director: Naim Alkhouri, MD, FAASLD

Course Faculty: Elisabetta Bugianesi, MD, PhD, and Michael Trauner, MD.

Presented at the United European Gastroenterology 2024 meeting, this activity presents emerging considerations around optimizing the management of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The recent approval in the United States of the first disease-specific therapy has created the potential for improved patient-centered care. Leading gastroenterology and hepatology experts discuss the best methods for screening, diagnosis, and treatment in this new era of disease-specific care.

Credit Available: 1.00 AMA PRA Category 1 credit(s)

Course Director: Meena B. Bansal, MD, FAASLD

Course Faculty: Juan M. Pericàs, MD, MPH, PhD, and Michael Roden, MD

Presented at the European Association for the Study of Diabetes 2024 meeting, this activity explores considerations around screening for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) in patients with type 2 diabetes. Current clinical trial data of MASH-specific therapies will be examined along with the mechanism of action of thyroid hormone receptor- b (THR-b) agonists. With the recent approval in the United States of the first MASH-specific therapy ushers in a new era for patient-centered care, several case-based scenarios will examine the most current approaches to screening, diagnosis, and treatment.

Credit Available: 1.00 AMA PRA Category 1 credit(s)

Course Director: Meena B. Bansal, MD, FAASLD

Course Faculty: Quentin M. Anstee, MBBS, PhD, FRCP, and Laurent Castera, MD, PhD.

Presented at the Paris MASH 2024 meeting, this activity examines emerging treatments that reduce fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH). The recent approval in the United States of the first disease-specific therapy has created the potential for improved patient-centered care. Find out how hepatology thought leaders from across the globe are utilizing noninvasive testing to identify and risk stratify patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and MASH. Case-based discussions reveal how to individualize treatment and optimize outcomes in this new era of patient care.

Credit Available: 1.00 AMA PRA Category 1 credit(s)

Course Director: Meena B. Bansal, MD, FAASLD

Course Faculty: Quentin M. Anstee, MBBS, PhD, FRCP, and Elisabetta Bugianesi, MD, PhD.

Presented at the International Liver Congress, EASL 2024, this activity will explore new innovations in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The recent approval of the first disease-specific therapy ushers in a new era for patient-centered care. Hear leading hepatologists from around the world consider the recent advancements in treatment through case-based discussions. Also, find out the best ways to identify patients who will benefit most in this new area of disease-specific care.

Credit Available: 1.25 AMA PRA Category 1 credit(s)

Course Director: Meena B. Bansal, MD, FAASLD

Course Faculty: Naim Alkhouri, MD, FAASLD and Mazen Noureddin, MD, MHSc

Presented at Digestive Disease Week, DDW 2024, this activity explores the latest clinical efficacy and safety data of approved and emerging disease-specific therapies for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Hepatology experts will discuss the mechanism of action of the first US Food and Drug Administration-approved thyroid hormone receptor-β (THR-β) agonist and examine case-based scenarios for optimizing pharmacologic management MASLD/MASH in this new treatment era. Considerations around disease staging will also be presented to ensure optimal patient management.